Skip to main content

Table 2 Antagonistic 2-agents combinations

From: Inference of synergy/antagonism between anticancer drugs from the pooled analysis of clinical trials

Agent 1 Agent 2 Standard of care* Expected ORR 1 Observed ORR 2 p antagonism Cancer subtype
Docetaxel Topotecan No 42 12 2.94E-11 Lung, ovarian cancer
Bortezomib Rituximab No 78 53 1.20E-09 Lymphoma
Temozolomide Alpha-interferon No 38 18 5.87E-08 Melanoma
Capecitabine Bortezomib No 58 14 9.02E-08 Breast cancer
Fludarabine Alemtuzumab No 83 64 1.27E-07 CLL, leukemia
Bevacizumab Temozolomide No 48 16 1.41E-07 Melanoma
Capecitabine Trimetrexate No 45 6 2.15E-06 Colorectal cancer
Docetaxel Irinotecan No 37 18 1.15E-05 Gastric, lung, ovarian cancer
Bortezomib Temsirolimus No 64 30 1.25E-05 Myeloma
Temozolomide Interleukin-2 No 49 16 1.97E-05 Melanoma
Docetaxel Gefitinib No 71 31 2.29E-05 Lung cancer
Docetaxel 5-fluorouracil No 38 25 1.71E-04 Gastric, head and neck cancer
Rituximab Temsirolimus No 75 59 2.44E-03 Lymphoma
Temozolomide Radiation No 64 46 2.51E-03 Breast cancer
Fludarabine Alpha-interferon No 76 52 2.55E-03 Lymphoma
G-CSF Rituximab No 71 61 4.69E-03 CLL, lymphoma
Doxorubicin Bevacizumab No 40 21 9.11E-03 Breast cancer
Docetaxel Imatinib No 46 28 2.09E-02 Breast cancer
Docetaxel Capecitabine Yes 49 43 4.48E-02 Breast, gastric cancer
Vinorelbine Mitoxantrone No 42 29 4.62E-02 Breast cancer
  1. *By National Comprehensive Cancer Network (NCCN) guidelines.
  2. The combinations with an observed ORR (ORR0) that is significantly lower than the expected ORR in the absence of agent interactions (ORR1).